Trial
NCT02858362
Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With Duchenne Muscular Dystrophy (DMD)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Summit Therapeutics
Collaborators
—
Condition
Duchenne Muscular Dystrophy
Intervention
Ezutromid
Why stopped
The study was terminated due to lack of efficacy in Cohorts 1 and 2.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-01-02